CRD-B
Crawford & Company
There isn't enough reported data to score CRD-B yet.
MS
Morgan Stanley
MS's fundamentals are strong: revenue grew 16% and earnings per share grew 29%. At 15x earnings, it's trading in line with its usual 14x. Analysts expect earnings growth.
CRD-B Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| N/A | |
| N/A |
CRD-B's revenue and profitability are currently stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CRD-B.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
CRD-B PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 11x | $11.49 | — |
| Cheap | 12x | $8.64 | -25% |
| Fair | 19x | $13.43 | +17% |
| Current | 22x | $11.49 | — |
| Expensive | 29x | $21.04 | +83% |
Historical ranges are pointers, not guarantees.
CRD-B has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
CRD-B Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect CRD-B's earnings to grow, with its revenue and profitability holding steady.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
MS has the edge over CRD-B on the outlook, with more favorable revenue and profitability expectations.
CRD-B Earnings Per Share
CRD-B and MS do not have enough comparable growth data to identify a winner.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS's earnings per share have climbed steadily: $12.60 over the past year, up 29% from the year before, and higher year over year for 10 quarters in a row.
CRD-B Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $329.9M | -0.9% |
| Q2 2026 | $330M | -1.4% |
| Q1 2026 | $320.1M | -1% |
| Q4 2025 | $320.1M | -11% |
| Q3 2025 | $332.8M | -2.9% |
| Q2 2025 | $334.6M | +2.4% |
| Q1 2025 | $323.3M | +3.3% |
| Q4 2024 | $358.3M | +12% |
CRD-B's revenue grew through 2022 and has held roughly level since: $330M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.3% | +1.1 points |
| Q2 2026 | 6.4% | +1.6 points |
| Q1 2026 | 2.9% | -0.7 points |
| Q4 2025 | -1.3% | -4.6 points |
| Q3 2025 | 6.2% | +1.2 points |
| Q2 2025 | 4.8% | +0.1 points |
| Q1 2025 | 3.6% | +1.6 points |
| Q4 2024 | 3.4% | +3.2 points |
CRD-B's operating margin was 7.3% last quarter, up 1.1 points from the same quarter a year ago, near the top of its range since 2019.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over CRD-B on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS has the edge over CRD-B on profitability, with a higher operating margin.
CRD-B Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $5M | -83% |
| Q2 2026 | $18.6M | -45% |
| Q1 2026 | $1.4M | +$16.3M |
| Q4 2025 | $46.9M | +26% |
| Q3 2025 | $29.3M | +65% |
| Q2 2025 | $33.6M | +188% |
| Q1 2025 | -$14.9M | +$6.4M |
| Q4 2024 | $37.3M | +9.1% |
CRD-B has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
CRD-B Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.9% | -947K shares |
| 1 year | -3.2% | -1.6M shares |
| 3 years | -2.5% | -1.2M shares |
| 5 years | -10% | -5.4M shares |
| Available history | -10% | -5.5M shares |
CRD-B has the edge over MS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $13.5M |
| Q2 2026 | $3.5M |
| Q1 2026 | $5.5M |
| Q4 2025 | $7.6M |
| Q3 2025 | $3M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $263,000 |
CRD-B spent $30M buying back its own shares over the past year, about nine times what it spent the year before.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has 1.6B diluted shares, down 1.5% from a year ago.
CRD-B Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.6x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.5x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 2.0x | Moderate |
| Q4 2024 | 1.9x | Healthy |
CRD-B has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
CRD-B Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.8 | Neutral |
| Stochastic | 35.7 | Neutral |
CRD-B's weekly RSI is 52 (neutral) and its Stochastic is 36 (neutral).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
CRD-B PE vs Financial Services Sector
| Metric | CRD-B | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 13x | 65% above |
| PE % | 63 | 63 | Same percentile |
CRD-B is trading at 22x earnings, a 65% premium to the Financial Services sector's median of 13x, though its earnings don't support one.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS has the edge over CRD-B on valuation relative to its sector.
CRD-B Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.8 | 2.5% below |
| 20 week MA | $11.5 | 0.3% below |
| 50 week MA | $10.9 | 5.6% above |
| 100 week MA | $10.9 | 5.4% above |
| 200 week MA | $10.4 | 10% above |
CRD-B has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 10% above its 200-week average.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
CRD-B Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.1 | $7.49 | -33% |
| 2021 | $7.49 | $7.51 | +0.3% |
| 2022 | $7.51 | $5.55 | -26% |
| 2023 | $5.55 | $13.2 | +137% |
| 2024 | $13.2 | $11.5 | -13% |
| 2025 | $11.5 | $11.9 | +3.6% |
| 2026 YTD | $11.9 | $11.5 | -3.2% |
CRD-B has finished lower in three of the last six years. It's down 3.2% so far in 2026.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has the edge over CRD-B on returns for 2026, with the stronger performance.